Pharma Pulse 4/11/25: Long-Term Sustainability for Diverse Trial Initiatives, Payers Consider Policy Options for GLP-1 Access & more

Long-Term Sustainability for Diverse Trial Initiatives

LaShell Robinson, head of global feasibility and trial equity at Takeda, discusses how Takeda will ensure that diversity and inclusion remain a priority in its clinical trials moving forward.

Payers Consider Policy Options for Access to GLP-1 Obesity Medications

A new paper by the Institute for Clinical and Economic Review (ICER) looks at the cost-effectiveness versus affordability issue of obesity medications such as Wegovy and Zepbound.

Novartis Pledges $23 Billion US Investment as Tariffs Loom

Swiss pharmaceutical giant Novartis AG said it would invest $23 billion in the US over the next five years to ensure all its key drugs for Americans are made in the country, news that comes as President Donald Trump has promised to impose tariffs on global drugmakers.

Survey Reveals: Americans Surprised by Prescription Costs but Rarely Discuss Financial Challenges With Pharmacists

New research from Lumicera Health Services, the specialty pharmacy subsidiary of Navitus Health Solutions, reveals a dual challenge in healthcare today: many Americans are feeling the strain of prescription costs, yet most aren't taking full advantage of the pharmacists they trust. A survey of 2,000 Americans aged 18+ found that 75% have been surprised by the cost of a medication – but few are initiating conversations that could lead to solutions. 74% of respondents have never discussed financial challenges with their doctor or pharmacist.

Chris O'Dell on LinkedIn

Thanks Pharamceutical Commerce! This executive order should help patients understand what the are going to pay for drugs before they get them.

Have news you want us to share in Pharma Pulse? Reach out to Editor Miranda Schmalfuhs